SUMO E3 ligases SUMOylate target proteins (Homo sapiens)

From WikiPathways

Jump to: navigation, search
3, 14, 18-20, 26...15, 23, 41cytosolnucleoplasmmitochondrionSUMOylation ofSUMOylationproteinsSUMOylation ofintracellularreceptorsSUMOylation ofchromatinorganizationproteinsSUMOylation ofimmune responseproteinsSUMO1-C93-UBE2I UBE2ISUMOylation of DNAreplicationproteinsSUMO1:RANGAP1homodimerRANGAP1 SUMOylation of DNAmethylationproteinsSUMO1-K524-RANGAP1 SUMOylation of DNAdamage response andrepair proteinsRANGAP1-G97-SUMO1 SUMOylation oftranscriptionfactorsRANGAP1 homodimerSUMOylation of RNAbinding proteinsSUMOylation ofubiquitinylationproteinsSUMO1:C93-UBE2ISUMOylation oftranscriptioncofactorsUBE2I-G97-SUMO1 341612, 8, 11, 22, 42...24, 33, 39, 409, 12, 17, 25, 324-6, 10, 21...4-6, 3050131, 4827, 287, 5213, 44


Description

SUMO proteins are conjugated to lysine residues of target proteins via an isopeptide bond with the C-terminal glycine of SUMO (reviewed in Zhao 2007, Gareau and Lima 2010, Hannoun et al. 2010, Citro and Chiocca 2013, Yang and Chiang 2013). Proteomic analyses indicate that SUMO is conjugated to hundreds of proteins and most targets of SUMOylation are nuclear (Vertegal et al. 2006, Bruderer et al. 2011, Tatham et al. 2011, Da Silva et al. 2012, Becker et al. 2013). Within the nucleus SUMOylation targets include transcription factors (TFs), transcription cofactors (TCs), intracellular (nuclear) receptors, RNA binding proteins, RNA splicing proteins, polyadenylation proteins, chromatin organization proteins, DNA replication proteins, DNA methylation proteins, DNA damage response and repair proteins, immune response proteins, SUMOylation proteins, and ubiquitinylation proteins. Mitochondrial fission proteins are SUMOylated at the mitochondrial outer membrane.
UBE2I (UBC9), the E2 activating enzyme of the SUMO pathway, is itself also a SUMO E3 ligase. Most SUMOylation reactions will proceed with only the substrate protein and the UBE2I:SUMO thioester conjugate. The rates of some reactions are further enhanced by the action of other E3 ligases such as RANBP2. These E3 ligases catalyze SUMO transfer to substrate by one of two basic mechanisms: they interact with both the substrate and UBE2I:SUMO thus bringing them into proximity or they enhance the release of SUMO from UBE2I to the substrate.
In the cell SUMO1 is mainly concentrated at the nuclear membrane and in nuclear bodies. Most SUMO1 is conjugated to RANGAP1 near the nuclear pore. SUMO2 is at least partially cytosolic and SUMO3 is located mainly in nuclear bodies. Most SUMO2 and SUMO3 is unconjugated in unstressed cells and becomes conjugated to target proteins in response to stress (Golebiowski et al. 2009). Especially notable is the requirement for recruitment of SUMO to sites of DNA damage where conjugation to targets seems to coordinate the repair process (Flotho and Melchior 2013).
Several effects of SUMOylation have been described: steric interference with protein-protein interactions, interference with other post-translational modifications such as ubiquitinylation and phosphorylation, and recruitment of proteins that possess a SUMO-interacting motif (SIM) (reviewed in Zhao 2007, Flotho and Melchior 2013, Jentsch and Psakhye 2013, Yang and Chiang 2013). In most cases SUMOylation inhibits the activity of the target protein.
The SUMOylation reactions included in this module have met two criteria: They have been verified by assays of individual proteins (as opposed to mass proteomic assays) and the effect of SUMOylation on the function of the target protein has been tested. View original pathway at Reactome.

Comments

Reactome-Converter 
Pathway is converted from Reactome ID: 3108232
Reactome-version 
Reactome version: 75
Reactome Author 
Reactome Author: May, Bruce

Try the New WikiPathways

View approved pathways at the new wikipathways.org.

Quality Tags

Ontology Terms

 

Bibliography

View all...
  1. Bischoff FR, Klebe C, Kretschmer J, Wittinghofer A, Ponstingl H.; ''RanGAP1 induces GTPase activity of nuclear Ras-related Ran.''; PubMed Europe PMC Scholia
  2. Ulrich HD.; ''Ubiquitin and SUMO in DNA repair at a glance.''; PubMed Europe PMC Scholia
  3. Becker J, Barysch SV, Karaca S, Dittner C, Hsiao HH, Berriel Diaz M, Herzig S, Urlaub H, Melchior F.; ''Detecting endogenous SUMO targets in mammalian cells and tissues.''; PubMed Europe PMC Scholia
  4. Lyst MJ, Stancheva I.; ''A role for SUMO modification in transcriptional repression and activation.''; PubMed Europe PMC Scholia
  5. Garcia-Dominguez M, Reyes JC.; ''SUMO association with repressor complexes, emerging routes for transcriptional control.''; PubMed Europe PMC Scholia
  6. Gill G.; ''Something about SUMO inhibits transcription.''; PubMed Europe PMC Scholia
  7. Denis H, Ndlovu MN, Fuks F.; ''Regulation of mammalian DNA methyltransferases: a route to new mechanisms.''; PubMed Europe PMC Scholia
  8. Jackson SP, Durocher D.; ''Regulation of DNA damage responses by ubiquitin and SUMO.''; PubMed Europe PMC Scholia
  9. Wan J, Subramonian D, Zhang XD.; ''SUMOylation in control of accurate chromosome segregation during mitosis.''; PubMed Europe PMC Scholia
  10. Lomelí H, Vázquez M.; ''Emerging roles of the SUMO pathway in development.''; PubMed Europe PMC Scholia
  11. Bologna S, Ferrari S.; ''It takes two to tango: Ubiquitin and SUMO in the DNA damage response.''; PubMed Europe PMC Scholia
  12. Dieckman LM, Freudenthal BD, Washington MT.; ''PCNA structure and function: insights from structures of PCNA complexes and post-translationally modified PCNA.''; PubMed Europe PMC Scholia
  13. Hsiao HH, Meulmeester E, Frank BT, Melchior F, Urlaub H.; ''"ChopNSpice," a mass spectrometric approach that allows identification of endogenous small ubiquitin-like modifier-conjugated peptides.''; PubMed Europe PMC Scholia
  14. Da Silva-Ferrada E, Lopitz-Otsoa F, Lang V, Rodríguez MS, Matthiesen R.; ''Strategies to Identify Recognition Signals and Targets of SUMOylation.''; PubMed Europe PMC Scholia
  15. Knipscheer P, Flotho A, Klug H, Olsen JV, van Dijk WJ, Fish A, Johnson ES, Mann M, Sixma TK, Pichler A.; ''Ubc9 sumoylation regulates SUMO target discrimination.''; PubMed Europe PMC Scholia
  16. Wilkinson KA, Henley JM.; ''Mechanisms, regulation and consequences of protein SUMOylation.''; PubMed Europe PMC Scholia
  17. Gazy I, Kupiec M.; ''The importance of being modified: PCNA modification and DNA damage response.''; PubMed Europe PMC Scholia
  18. Vertegaal AC, Andersen JS, Ogg SC, Hay RT, Mann M, Lamond AI.; ''Distinct and overlapping sets of SUMO-1 and SUMO-2 target proteins revealed by quantitative proteomics.''; PubMed Europe PMC Scholia
  19. Hannoun Z, Greenhough S, Jaffray E, Hay RT, Hay DC.; ''Post-translational modification by SUMO.''; PubMed Europe PMC Scholia
  20. Gareau JR, Lima CD.; ''The SUMO pathway: emerging mechanisms that shape specificity, conjugation and recognition.''; PubMed Europe PMC Scholia
  21. Ouyang J, Valin A, Gill G.; ''Regulation of transcription factor activity by SUMO modification.''; PubMed Europe PMC Scholia
  22. Cremona CA, Sarangi P, Zhao X.; ''Sumoylation and the DNA damage response.''; PubMed Europe PMC Scholia
  23. Lee GW, Melchior F, Matunis MJ, Mahajan R, Tian Q, Anderson P.; ''Modification of Ran GTPase-activating protein by the small ubiquitin-related modifier SUMO-1 requires Ubc9, an E2-type ubiquitin-conjugating enzyme homologue.''; PubMed Europe PMC Scholia
  24. Treuter E, Venteclef N.; ''Transcriptional control of metabolic and inflammatory pathways by nuclear receptor SUMOylation.''; PubMed Europe PMC Scholia
  25. Watts FZ.; ''The role of SUMO in chromosome segregation.''; PubMed Europe PMC Scholia
  26. Yang XJ, Chiang CM.; ''Sumoylation in gene regulation, human disease, and therapeutic action.''; PubMed Europe PMC Scholia
  27. Liu X, Wang Q, Chen W, Wang C.; ''Dynamic regulation of innate immunity by ubiquitin and ubiquitin-like proteins.''; PubMed Europe PMC Scholia
  28. Kracklauer MP, Schmidt C.; ''At the crossroads of SUMO and NF-kappaB.''; PubMed Europe PMC Scholia
  29. Citro S, Chiocca S.; ''Sumo paralogs: redundancy and divergencies.''; PubMed Europe PMC Scholia
  30. Girdwood DW, Tatham MH, Hay RT.; ''SUMO and transcriptional regulation.''; PubMed Europe PMC Scholia
  31. Filosa G, Barabino SM, Bachi A.; ''Proteomics strategies to identify SUMO targets and acceptor sites: a survey of RNA-binding proteins SUMOylation.''; PubMed Europe PMC Scholia
  32. Watts FZ.; ''Sumoylation of PCNA: Wrestling with recombination at stalled replication forks.''; PubMed Europe PMC Scholia
  33. Wadosky KM, Willis MS.; ''The story so far: post-translational regulation of peroxisome proliferator-activated receptors by ubiquitination and SUMOylation.''; PubMed Europe PMC Scholia
  34. Cubeñas-Potts C, Matunis MJ.; ''SUMO: a multifaceted modifier of chromatin structure and function.''; PubMed Europe PMC Scholia
  35. Jentsch S, Psakhye I.; ''Control of nuclear activities by substrate-selective and protein-group SUMOylation.''; PubMed Europe PMC Scholia
  36. Bruderer R, Tatham MH, Plechanovova A, Matic I, Garg AK, Hay RT.; ''Purification and identification of endogenous polySUMO conjugates.''; PubMed Europe PMC Scholia
  37. Zhao J.; ''Sumoylation regulates diverse biological processes.''; PubMed Europe PMC Scholia
  38. Tatham MH, Matic I, Mann M, Hay RT.; ''Comparative proteomic analysis identifies a role for SUMO in protein quality control.''; PubMed Europe PMC Scholia
  39. Anbalagan M, Huderson B, Murphy L, Rowan BG.; ''Post-translational modifications of nuclear receptors and human disease.''; PubMed Europe PMC Scholia
  40. Knutson TP, Lange CA.; ''Dynamic regulation of steroid hormone receptor transcriptional activity by reversible SUMOylation.''; PubMed Europe PMC Scholia
  41. Mahajan R, Delphin C, Guan T, Gerace L, Melchior F.; ''A small ubiquitin-related polypeptide involved in targeting RanGAP1 to nuclear pore complex protein RanBP2.''; PubMed Europe PMC Scholia
  42. Praefcke GJ, Hofmann K, Dohmen RJ.; ''SUMO playing tag with ubiquitin.''; PubMed Europe PMC Scholia
  43. Golebiowski F, Matic I, Tatham MH, Cole C, Yin Y, Nakamura A, Cox J, Barton GJ, Mann M, Hay RT.; ''System-wide changes to SUMO modifications in response to heat shock.''; PubMed Europe PMC Scholia
  44. Bernier-Villamor V, Sampson DA, Matunis MJ, Lima CD.; ''Structural basis for E2-mediated SUMO conjugation revealed by a complex between ubiquitin-conjugating enzyme Ubc9 and RanGAP1.''; PubMed Europe PMC Scholia
  45. Dou H, Huang C, Van Nguyen T, Lu LS, Yeh ET.; ''SUMOylation and de-SUMOylation in response to DNA damage.''; PubMed Europe PMC Scholia
  46. Bekker-Jensen S, Mailand N.; ''The ubiquitin- and SUMO-dependent signaling response to DNA double-strand breaks.''; PubMed Europe PMC Scholia
  47. van Wijk SJ, Müller S, Dikic I.; ''Shared and unique properties of ubiquitin and SUMO interaction networks in DNA repair.''; PubMed Europe PMC Scholia
  48. Li T, Evdokimov E, Shen RF, Chao CC, Tekle E, Wang T, Stadtman ER, Yang DC, Chock PB.; ''Sumoylation of heterogeneous nuclear ribonucleoproteins, zinc finger proteins, and nuclear pore complex proteins: a proteomic analysis.''; PubMed Europe PMC Scholia
  49. Flotho A, Melchior F.; ''Sumoylation: a regulatory protein modification in health and disease.''; PubMed Europe PMC Scholia
  50. Wilson VG, Heaton PR.; ''Ubiquitin proteolytic system: focus on SUMO.''; PubMed Europe PMC Scholia
  51. Psakhye I, Jentsch S.; ''Protein group modification and synergy in the SUMO pathway as exemplified in DNA repair.''; PubMed Europe PMC Scholia
  52. Xu F, Mao C, Ding Y, Rui C, Wu L, Shi A, Zhang H, Zhang L, Xu Z.; ''Molecular and enzymatic profiles of mammalian DNA methyltransferases: structures and targets for drugs.''; PubMed Europe PMC Scholia

History

CompareRevisionActionTimeUserComment
115023view16:56, 25 January 2021ReactomeTeamReactome version 75
113468view11:54, 2 November 2020ReactomeTeamReactome version 74
112829view18:34, 9 October 2020DeSlOntology Term : 'sumoylation pathway' added !
112776view16:17, 9 October 2020ReactomeTeamNew pathway

External references

DataNodes

View all...
NameTypeDatabase referenceComment
RANGAP1 ProteinP46060 (Uniprot-TrEMBL)
RANGAP1 homodimerComplexR-HSA-9626018 (Reactome)
RANGAP1-G97-SUMO1 ProteinP63165 (Uniprot-TrEMBL)
SUMO1-C93-UBE2I ProteinP63279 (Uniprot-TrEMBL)
SUMO1-K524-RANGAP1 ProteinP46060 (Uniprot-TrEMBL)
SUMO1:C93-UBE2IComplexR-HSA-2993783 (Reactome)
SUMO1:RANGAP1 homodimerComplexR-HSA-9624892 (Reactome)
SUMOylation of

SUMOylation

proteins
PathwayR-HSA-4085377 (Reactome) SUMOylation processes themselves can be controlled by SUMOylation (reviewed in Wilkinson and Henley 2010). The SUMO E3 ligases PIAS4, RANBP2, and TOPORS are SUMOylated, as is the single SUMO E2 enzyme, UBE2I (UBC9). SUMOylation affects the subcellular location of PIAS4 and TOPORS and affects the activity of PIAS4 and UBE2I.
SUMOylation of

chromatin organization

proteins
PathwayR-HSA-4551638 (Reactome) SUMOylation of proteins involved in chromatin organization regulates gene expression in several ways: direct influence on catalytic activity of enzymes that modify chromatin, recruitment of proteins that form repressive (e.g. PRC1) or activating complexes on chromatin, recruitment of proteins to larger bodies (e.g PML bodies) in the nucleus (reviewed in Cubenas-Potts and Matunis 2013).
SUMOylation of

immune response

proteins
PathwayR-HSA-4755510 (Reactome) NF-kappaB transcription factors are sequestered in the cytosol due to their association with IkappaB. During activation of NF-kappaB, IKK phosphorylates IkappaB, releasing NF-kappaB for importation into the nucleus. NF-kappaB transcription factors, the NFKBIA component of IkappaB, and subunits of the IKK complex can be SUMOylated (reviewed in Kracklauer and Schmidt 2003, Liu et al. 2013). SUMOylations of IkappaB, NFKBIA, and RELA inhibit NF-kappaB signaling; SUMOylation of NFKB2 is required for proteolytic processing.
SUMOylation of

intracellular

receptors
PathwayR-HSA-4090294 (Reactome) At least 17 nuclear receptors have been discovered to be SUMOylated (reviewed in Treuter and Venteclef 2011, Wadosky et al. 2012, Knutson and Lange 2013). In all but a few cases (notably AR and RORA) SUMOylation causes transcriptional repression. Repression by SUMOylation is believed to occur through several mechanisms: interference with DNA binding, recruitment of corepressors, retention of corepressors at non-target promoters (transrepression), re-localization of nuclear receptors within the nucleus, interference with dimerization of receptors, and interference (crosstalk) with other post-translational modifications. SUMOylation of receptors affects inflammation and disease processes (Anbalagan et al. 2012).
SUMOylation of

transcription

cofactors
PathwayR-HSA-3899300 (Reactome) SUMO1,2, and 3 are predominantly located in the nucleus and targets of SUMOylation are predominantly nuclear. Transcription cofactors are nuclear proteins that generally do not bind DNA themselves but interact with DNA-bound factors and influence transcription. SUMOylation of transcription cofactors usually inhibits the activity of the cofactor (reviewed in Girdwood et al. 2004, Gill 2005, Lyst and Stancheva 2007, Garcia-Dominguez and Reyes 2009). In the cases of coactivators such as PPARGC1A (PGC-1alpha) this results in decreased transcription; in the cases of corepressors such as MBD1 this results in increased transcription.
SUMOylation of

transcription

factors
PathwayR-HSA-3232118 (Reactome) Proteins classified as transcription factors constitute a disproportionate number of SUMOylation targets. In most cases SUMOylation inhibits transcriptional activation, however in some cases such as TP53 (p53) SUMOylation can enhance activation. Inhibition of transcription by SUMOylation may be due to interference with DNA binding, re-localization to inactive nuclear bodies, or recruitment of repressive cofactors such as histone deacetylases (reviewed in Girdwood et al. 2004, Gill 2005).
SUMOylation of

ubiquitinylation

proteins
PathwayR-HSA-3232142 (Reactome) Several ubiquitin E3 ligases are regulated by SUMOylation (reviewed in Wilson and Heaton 2008). SUMOylation appears to be necessary for nuclear import of MDM2, the E3 ligase that ubiquitinylates TP53 (p53). SUMOylation of VHL abolishes its ubiquitin ligase activity. HERC2, RNF168, and BRCA1 are ubiquitin ligases that are SUMOylated during DNA damage response and repair.
SUMOylation of DNA

damage response and

repair proteins
PathwayR-HSA-3108214 (Reactome) Several factors that participate in DNA damage response and repair are SUMOylated (reviewed in Dou et al. 2011, Bekker-Jensen and Mailand 2011, Ulrich 2012, Psakhye and Jentsch 2012, Bologna and Ferrari 2013, Flotho and Melchior 2013, Jackson and Durocher 2013). SUMOylation can alter enzymatic activity and protein stability or it can serve to recruit additional factors. For example, SUMOylation of Thymine DNA glycosylase (TDG) causes TDG to lose affinity for its product, an abasic site opposite a G residue, and thus increases turnover of the enzyme. During repair of double-strand breaks SUMO1, SUMO2, SUMO3, and the SUMO E3 ligases PIAS1 and PIAS4 accumulate at double-strand breaks where BRCA1, HERC1, RNF168, MDC1, and TP53BP1 are SUMOylated. SUMOylation of BRCA1 may increase its ubiquitin ligase activity while SUMOylation of MDC1 and HERC2 appears to play a role in recruitment of proteins such as RNF4 and RNF8 to double strand breaks. Similarly SUMOylation of RPA1 (RPA70) recruits RAD51 in the homologous recombination pathway.
SUMOylation of DNA

methylation

proteins
PathwayR-HSA-4655427 (Reactome) The known DNA methyltransferases (DNMT1, DNMT3A, and DNMT3B) can be SUMOylated (reviewed in Xu et al. 2010, Denis et al. 2011). SUMOylation affects the catalytic activity of DNMT1 and the protein interactions of DNMT3A.
SUMOylation of DNA

replication

proteins
PathwayR-HSA-4615885 (Reactome) The sliding clamp protein PCNA, Aurora-A, Aurora-B, Borealin, and various topoisomerases can be SUMOylated (reviewed in Wan et al. 2012). SUMOylation of PCNA appears to reduce formation of double-strand breaks and inappropriate recombination (reviewed in Watts 2006, Watts 2007, Dieckman et al. 2012, Gazy and Kupiec 2012). SUMOylation of Aurora-A, Aurora-B, and Borealin is necessary for proper chromosome segregation. SUMOylation of topoisomerases is observed in response to damage caused by inhibitors of topoisomerases.
SUMOylation of RNA binding proteinsPathwayR-HSA-4570464 (Reactome) SUMOylation of RNA-binding proteins (Li et al. 2004, reviewed in Filosa et al. 2013) alters their interactions with nucleic acids and with proteins. Whereas SUMOylation of HNRNPC decreases its affinity for nucleic acid (ssDNA), SUMOylation of NOP58 is required for binding of snoRNAs. SUMOylation of HNRNPK is required for its coactivation of TP53-dependent transcription.
UBE2I-G97-SUMO1 ProteinP63165 (Uniprot-TrEMBL)
UBE2IProteinP63279 (Uniprot-TrEMBL)

Annotated Interactions

View all...
SourceTargetTypeDatabase referenceComment
R-HSA-3000449 (Reactome) The majority of RANGAP1 in the cell is conjugated with SUMO1 by the E3 ligase UBE2l (Ubc9) (Knipscheer et al. 1998, Lee et al. 1998). SUMO1 targets RANGAP1 to the nucleoporin RANBP2 (Mahajan et al. 1997).
RANGAP1 homodimerR-HSA-3000449 (Reactome)
SUMO1:C93-UBE2IR-HSA-3000449 (Reactome)
SUMO1:C93-UBE2Imim-catalysisR-HSA-3000449 (Reactome)
SUMO1:RANGAP1 homodimerArrowR-HSA-3000449 (Reactome)
UBE2IArrowR-HSA-3000449 (Reactome)
Personal tools